Key result
Sampatrilat (50-200 mg daily) significantly lowered clinic and ambulatory blood pressure after 10 days of treatment, demonstrating increasing efficacy compared to lisinopril over time.
Why the study?
Does sampatrilat lower blood pressure and alter biomarkers compared to lisinopril or placebo in patients with essential hypertension?
Population
124 patients with essential hypertension, mean blood pressure 162/102 mm Hg
Comparison
Sampatrilat 50 mg, 100 mg, or 200 mg once daily… vs Lisinopril 20 mg once daily or placebo for 10 days
Design
RCT, randomized in a parallel-group design, double-blind
Follow-up
10 days
Authors
Loading...
Supports short-term BP lowering in hypertension; extends dual ACE-NEP inhibition evidence beyond ACEI monotherapy.
RCT (n=124)
Double-blind
parallel-group
Does sampatrilat lower blood pressure and alter biomarkers compared to lisinopril or placebo in patients with essential hypertension?
Sampatrilat, a combined ACE-NEP inhibitor, effectively lowers blood pressure over 10 days, likely mediated in part by NEP inhibition as evidenced by increased urinary cGMP.
Wallis et al. (1998) conducted an RCT in Essential hypertension (n=124). Sampatrilat vs. Lisinopril 20 mg or placebo was evaluated on Blood pressure, plasma ACE, renin activity, and urinary cGMP. Sampatrilat (50-200 mg daily) significantly lowered clinic and ambulatory blood pressure after 10 days of treatment, demonstrating increasing efficacy compared to lisinopril over time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: